|Bid||89.52 x 800|
|Ask||90.09 x 800|
|Day's range||87.60 - 89.90|
|52-week range||66.89 - 164.86|
|Beta (5Y monthly)||1.02|
|PE ratio (TTM)||208.91|
|Earnings date||26 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||99.31|
The first reason to buy DexCom stock is that it's slumping as a result of short-term issues that won't have much of an impact once they're resolved. Its latest continuous glucose monitor (CGM) in development for diabetes management, the G7, hit a snag in its approval process with regulators at the Food and Drug Administration (FDA). Then, when the G7 ultimately launches in the U.S., DexCom's revenue growth will likely pick up once more, and its stock price should follow.
DexCom has been doing better than big tech stocks that have had more notable stock splits this year.
Alphabet, Amazon, DexCom, Shopify, and Tesla have all announced stock splits this year -- but only one of these giants is a screaming buy.